Get the Stockscreener App
8.845
4.80%
0.405
Pre-market:
8.75
-0.095
-1.07%
Corvus Pharmaceuticals Inc stock is traded at $8.845, with a volume of 1.01M.
It is up +4.80% in the last 24 hours and up +15.77% over the past month.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
See More
Previous Close:
$8.44
Open:
$8.44
24h Volume:
1.01M
Relative Volume:
1.08
Market Cap:
$660.56M
Revenue:
-
Net Income/Loss:
$-27.03M
P/E Ratio:
-15.79
EPS:
-0.56
Net Cash Flow:
$-23.97M
1W Performance:
-2.48%
1M Performance:
+15.77%
6M Performance:
+135.87%
1Y Performance:
+10.15%
1-Day Range:
$8.40
$8.90
1-Week Range:
$8.03
$9.18
52-Week Range:
$2.54
$9.32
Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile
Name
Corvus Pharmaceuticals Inc
Sector
Industry
Phone
(650) 900-4520
Address
863 MITTEN ROAD, BURLINGAME, CA
Compare CRVS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRVS
Corvus Pharmaceuticals Inc
|
8.845 | 630.31M | 0 | -27.03M | -23.97M | -0.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-13-25 | Initiated | Barclays | Overweight |
| Jan-02-25 | Initiated | H.C. Wainwright | Buy |
| Aug-18-23 | Initiated | Oppenheimer | Outperform |
| Dec-01-21 | Resumed | Jefferies | Buy |
| May-27-21 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-10-21 | Downgrade | Mizuho | Buy → Neutral |
| Sep-12-19 | Initiated | Mizuho | Buy |
| May-29-19 | Initiated | ROTH Capital | Buy |
| Aug-24-17 | Upgrade | Credit Suisse | Underperform → Neutral |
| May-01-17 | Downgrade | Credit Suisse | Neutral → Underperform |
| Apr-18-16 | Initiated | Credit Suisse | Outperform |
| Apr-18-16 | Initiated | Guggenheim | Buy |
View All
Corvus Pharmaceuticals Inc Stock (CRVS) Latest News
You might want to take a look at Corvus Pharmaceuticals Inc (CRVS) now - Setenews
Will Corvus Pharmaceuticals Inc. stock split again soonMarket Performance Report & Growth Focused Investment Plans - Newser
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Corvus Pharmaceuticals (NASDAQ:CRVS) Stock Price Down 8%Here's What Happened - MarketBeat
Here's Why We're Not Too Worried About Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation - Yahoo Finance
Is Corvus Pharmaceuticals Inc. stock a buy before product launchesDividend Hike & Intraday High Probability Alerts - Newser
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Perhaps timely catching Corvus Pharmaceuticals Inc (CRVS) would be a good idea - Setenews
Corvus Pharmaceuticals: Trial Momentum Keeps Stock In Focus - RTTNews
What risks investors should watch in Corvus Pharmaceuticals Inc. stockWeekly Trend Summary & Weekly Watchlist for Consistent Profits - newser.com
Will Corvus Pharmaceuticals Inc. stock reach Wall Street targetsPortfolio Growth Summary & Technical Buy Zone Confirmation - newser.com
Is Corvus Pharmaceuticals Inc. stock affected by interest rate hikes2025 Geopolitical Influence & Consistent Profit Trading Strategies - newser.com
Is Corvus Pharmaceuticals Inc. stock supported by innovation pipeline2025 Analyst Calls & Consistent Profit Trading Strategies - newser.com
What valuation multiples suggest for Corvus Pharmaceuticals Inc. stockRecession Risk & AI Forecast Swing Trade Picks - newser.com
Corvus Pharmaceuticals Inc. stock momentum explainedWeekly Profit Report & Verified Swing Trading Watchlist - newser.com
Its Stock Has Paid Off Big Time For Corvus Pharmaceuticals Inc - Setenews
Corvus Pharmaceuticals Inc. recovery potential after sell offPortfolio Update Summary & Safe Capital Growth Tips - newser.com
Using RSI to spot recovery in Corvus Pharmaceuticals Inc.Earnings Growth Report & Long-Term Growth Portfolio Plans - newser.com
Combining price and volume data for Corvus Pharmaceuticals Inc.July 2025 Decliners & Reliable Momentum Entry Alerts - newser.com
Is Corvus Pharmaceuticals Inc. forming a bottoming baseTrade Risk Summary & Fast Moving Stock Watchlists - newser.com
What drives Corvus Pharmaceuticals Inc stock priceEarnings Miss Alerts & Free Wealth Planning Blueprints - earlytimes.in
Published on: 2025-11-28 13:27:18 - earlytimes.in
Is Corvus Pharmaceuticals Inc a good long term investmentEconomic Impact on Stocks & Double Digit Capital Growth - earlytimes.in
What machine learning models say about Corvus Pharmaceuticals Inc.Weekly Profit Analysis & Reliable Breakout Stock Forecasts - newser.com
How to build a dashboard for Corvus Pharmaceuticals Inc. stockJuly 2025 Selloffs & Fast Momentum Stock Entry Tips - newser.com
Is Corvus Pharmaceuticals Inc. stock a defensive play in 2025July 2025 Recap & Long-Term Safe Investment Ideas - newser.com
Should you wait for a breakout in Corvus Pharmaceuticals Inc.Index Update & Safe Entry Zone Tips - newser.com
Get in on Corvus Pharmaceuticals Inc’s (CRVS) buy-in window today! - Setenews
Mizuho Securities Keeps Their Buy Rating on Corvus Pharmaceuticals (CRVS) - The Globe and Mail
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q3 2025 Earnings Call Transcript - MSN
Corvus at Guggenheim Conference: Promising Trials and Financial Stability By Investing.com - Investing.com India
Corvus Pharmaceuticals Inc Stock (CRVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):